Lv51
1360 积分 2024-03-10 加入
Overall survival results from EVER-132-001, a phase 2b single-arm study of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer . Cancer Res 2024;84(9 Suppl): SABCS Abstract PO1-06-10
4天前
求助中
Schmid P, Cortes J, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024 Nov 28;391(21):1981-1991
6天前
已完结
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions. Front Immunol. 2024 Nov 1;15:1495675
6天前
已完结
Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors. Drug Dev Res. 2021 Dec;82(8):1096-1110
6天前
已完结
2024年度晚期乳腺癌共识与争议的现状及展望[J]. 中国癌症杂志,2025,35(3):263-273
9天前
已完结
发作性高血压临床诊治专家共识[J/OL].中华高血压杂志(中英文),1-14[2025-09-15]
17天前
已关闭
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis. 2022 Jul 6;74(12):2089-2114
18天前
已关闭
重症患儿万古霉素药代动力学的影响因素[J]. 中国小儿急救医学,2023,30(10):776-780
18天前
已完结
皖公网安备34019202002308
